Exciting News! Vorasidenib (brand name: Voranigo) has just been approved by the FDA for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation. Read more: https://t.co/G6FB95R7nj
I’m proud to join @NBTSTweets and fellow brain tumor advocates in urging @repmcgovern@senwarren@SenMarkey to support increased research funding and improved SSDI benefits to address the needs of the brain tumor community. #Head2Hill https://t.co/g1xGl7YBJX
Congress must #StopTheWait for SSDI and Medicare benefits for brain tumor patients. @RepKClark, please pass the Stop the Wait Act to make sure patients get the benefits they've earned!
Congress must #StopTheWait for SSDI and Medicare benefits for brain tumor patients. @senwarren@SenMarkey, thank you for cosponsoring the Stop the Wait Act to make sure patients get the benefits they've earned!